Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrizio Accardi

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
International Journal of Hematology|October 5, 2016
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?Valentina Marchica, Fabrizio Accardi, Paola Storti, et al.
Oncotarget|September 9, 2017
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory propertiesFederica Costa, Rosanna Vescovini, Marina Bolzoni, et al.
Oncotarget|September 17, 2017
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formationFederica Costa, Denise Toscani, Antonella Chillemi, et al.
Current Oncology (Toronto, Ont.)|November 24, 2023
Multiple Myeloma in 2023 Ways: From Trials to Real LifeManlio Fazio, Vittorio Del Fabro, Nunziatina Laura Parrinello, et al.
Haematologica|January 7, 2017
<i>IL21R</i> expressing CD14<sup>+</sup>CD16<sup>+</sup> monocytes expand in multiple myeloma patients leading to increased osteoclastsMarina Bolzoni, Domenica Ronchetti, Paola Storti, et al.
Blood|June 9, 2016
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive targetMarina Bolzoni, Martina Chiu, Fabrizio Accardi, et al.
The Lancet. Haematology|August 6, 2025
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trialSara Bringhen, Lorenzo Cani, Elisabetta Antonioli, et al.
Haematologica|March 19, 2026
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasoneCarmine Liberatore, Alfonso Piciocchi, Donatella Vincelli, et al.
Annals of Hematology|September 9, 2025
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapiesDanilo De Novellis, Salvatore Palmieri, Stefano Rocco, et al.
Annals of Hematology|October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) ItalyConcetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
International Journal of Hematology|October 5, 2016
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?Valentina Marchica, Fabrizio Accardi, Paola Storti, et al.
Oncotarget|September 9, 2017
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory propertiesFederica Costa, Rosanna Vescovini, Marina Bolzoni, et al.
Oncotarget|September 17, 2017
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formationFederica Costa, Denise Toscani, Antonella Chillemi, et al.
Current Oncology (Toronto, Ont.)|November 24, 2023
Multiple Myeloma in 2023 Ways: From Trials to Real LifeManlio Fazio, Vittorio Del Fabro, Nunziatina Laura Parrinello, et al.
Haematologica|January 7, 2017
<i>IL21R</i> expressing CD14<sup>+</sup>CD16<sup>+</sup> monocytes expand in multiple myeloma patients leading to increased osteoclastsMarina Bolzoni, Domenica Ronchetti, Paola Storti, et al.
Blood|June 9, 2016
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive targetMarina Bolzoni, Martina Chiu, Fabrizio Accardi, et al.
The Lancet. Haematology|August 6, 2025
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trialSara Bringhen, Lorenzo Cani, Elisabetta Antonioli, et al.
Haematologica|March 19, 2026
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasoneCarmine Liberatore, Alfonso Piciocchi, Donatella Vincelli, et al.
Annals of Hematology|September 9, 2025
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapiesDanilo De Novellis, Salvatore Palmieri, Stefano Rocco, et al.
Annals of Hematology|October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) ItalyConcetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
Pageof 3